Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Sonoma Pharmaceuticals Q2 revenue rises on strong US demand

By Reuters News


Overview

  • Healthcare product maker's fiscal Q2 revenue rose 28% yr/yr, led by 93% U.S. growth

  • Gross margin improved to 39% from 38% on higher revenue and better manufacturing processes

  • Company reported first-ever positive net income before taxes, reflecting higher revenue and stable expenses


Outlook

  • Company anticipates potential product launch with U.S. skincare partner in summer 2027

  • Sonoma expects Taiwan market entry pending regulatory approval and initial purchase order

  • Company sees growth opportunities in senior-care market for HOCl products


Result Drivers

  • U.S. DEMAND - Co said 93% U.S. revenue growth was driven by higher demand and increased sales from new and existing distributors

  • MANUFACTURING AND CUSTOMER MIX - Co attributed higher gross margin to improved manufacturing processes and changes in customer mix

  • OPERATING LEVERAGE - Co said stable operating expenses alongside revenue growth demonstrated operating leverage


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

$7.20 mln

Q2 EBITDA

$400,000

Q2 Gross Profit

$2.80 mln

Q2 Operating Expenses

$2.50 mln


Reuters Recommended Reads

  • Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

  • Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves

  • Nov 9 - Myomo Q3 revenue rises 22% to record high


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.